Piramal Pharma Limited announced its unaudited standalone financial results for the quarter ended December 31, 2025 (Q3 2026). The company’s total income stood at ₹1,291.96 crore. The company reported a net profit after tax of ₹128.91 crore. The Board of Directors approved these results in a meeting held on January 28, 2026.
Financial Performance Highlights
Piramal Pharma Limited has released its unaudited standalone financial results for Q3 2026, showcasing key financial metrics for the period. Key figures from the report include:
- Total Income: Recorded at ₹1,291.96 crore compared to ₹1,273.02 crore for the corresponding quarter of the previous year.
- Net Profit After Tax: Stood at ₹128.91 crore.
These results reflect the company’s performance during the quarter, demonstrating its financial activities and outcomes.
Review and Approval
The Audit Committee reviewed the financial results, and the Board of Directors approved them at a meeting held on January 28, 2026. The statutory auditors have also performed a limited review of these results, ensuring compliance and accuracy.
Impact of Labour Codes
The company addressed the impact of the new Labour Codes, noting an incremental impact of ₹26.94 crores, which has been presented as an exceptional item in the financial results for Q3 2026.
Other Key Points
- The company’s earnings per share (EPS) stood at ₹0.97.
Source: BSE
